読み込み中
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
終値時点
$0.80
−$0.036 · -4.31%
時間外
$0.8285
+$0.0285 · +3.56%
10月8日 18:14 ET
日中の時刻はETです。市場データは遅延する場合があります。
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
日中レンジ
現在 $0.80
52週レンジ
現在 $0.80
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
46
適正価値
センチメント
55
まちまち
リスク
73
高リスク
モメンタム
17
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
日中レンジ
現在 $0.80
52週レンジ
現在 $0.80
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 505.4万 USD | 337.8万 USD | 9万 USD | 11.1万 USD | 28.3万 USD |
| 販売・一般管理 | 3170.3万 USD | 1204.1万 USD | 517.2万 USD | 304.9万 USD | 289万 USD |
| 営業費用 | 3675.7万 USD | 1541.9万 USD | 526.2万 USD | 316万 USD | 317.3万 USD |
| 受取利息 | 2.8万 USD | 1.3万 USD | 1.5万 USD | 197.6万 USD | — |
| 支払利息 | 31.9万 USD | 150.6万 USD | 21.1万 USD | — | — |
| 減価償却費と償却費 | 242.5万 USD | 45.7万 USD | — | — | — |
| 営業利益 | −3675.7万 USD | −1541.9万 USD | −526.2万 USD | −316万 USD | −317.3万 USD |
| 純利益 | −3922.4万 USD | −1780.2万 USD | −53.5万 USD | −488.7万 USD | −365.7万 USD |
会社概要が更新されました 2026年10月8日.
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
